Corcept Therapeutics (CORT) AI Stock Analysis

• Market Cap: $4.80B
• Dividend Yield: N/A
• Average Volume (3M): 2.57M
• Price to Earnings (P/E): 52.8
• Beta (1Y): 0.48
• Revenue Growth: 17.92%
• EPS Growth: -26.13%
• Country: US
• Employees: 500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 105,188,220
• 10 Day Avg. Volume: 2,102,886
• 30 Day Avg. Volume: 2,573,484
• PEG Ratio: 1.15
• Price to Book (P/B): 7.65
• Price to Sales (P/S): 7.71
• P/FCF Ratio: 26.55
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 6.35
• Enterprise Value/Gross Profit: 6.46
• Enterprise Value/Ebitda: 64.92
• 1Y Price Target: $105.25
• Price Target Upside: 127.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $39.00 ▼(-15.62% Downside)

The score is primarily supported by strong financial health (very low leverage, solid ROE, high gross margin) and constructive business momentum from guidance and pipeline progress. These positives are meaningfully offset by very weak technical trend signals (price far below major moving averages) and profitability/cash-flow pressure, with valuation (high P/E) and mixed regulatory outcomes adding risk.

Positive Factors

Low leverage and strong equity ratio

A near-zero debt-to-equity ratio and high equity financing provide durable financial flexibility. This capital structure supports funding R&D, commercial expansion, and potential litigation or regulatory costs without relying on external debt, reducing bankruptcy and refinancing risk over the next several years.

Very high gross profit margin

Extremely high gross margins reflect significant pricing power and low incremental manufacturing costs for Korlym. Such structural margins support sustainable cash generation to fund clinical programs and commercialization even if operating expenses rise, preserving core profitability over multiple years.

Durable demand growth for Korlym

A 42.5% increase in tablets shipped and record prescriptions indicate persistent underlying patient demand, not a one-off sales spike. Ongoing pharmacy capacity fixes and planned additional specialty partners signal management is scaling distribution to sustain and grow this revenue base over the medium term.

Negative Factors

FDA Complete Response Letter for relacorilant

The CRL materially delays U.S. commercialization of relacorilant and requires additional evidence to satisfy benefit-risk. This regulatory setback extends development timelines and costs, postpones projected multibillion-dollar revenues, and increases execution risk for a key pipeline asset.

Declining net income and shrinking margins

A meaningful drop in net margin signals rising operating expenses or one-time charges that erode profitability. Sustained margin compression reduces free cash flow available for reinvestment, share repurchases, or buffering regulatory/pipeline setbacks, and could constrain strategic initiatives if not reversed.

Ongoing patent litigation over Korlym

Active patent litigation threatens exclusivity for Corcept's flagship product. A negative outcome could enable generic competition and materially reduce long-term revenue and high-margin cash flows. This legal overhang makes future growth more dependent on successful pipeline launches.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

How the Company Makes Money

Corcept Therapeutics generates revenue primarily through the sale of its flagship product, Korlym, which is prescribed for patients with Cushing's syndrome. The company also engages in research collaborations and partnerships that may provide additional funding and resources for the development of new therapies. Revenue is driven by both direct sales to healthcare providers and reimbursement from insurance companies. Additionally, Corcept's focus on expanding the indications for its existing products and developing new treatments contributes to its potential revenue growth, as successful clinical trials can lead to new market opportunities.

Corcept Therapeutics Financial Statement Overview

Summary

Strong overall fundamentals supported by very high gross margin (98.19% TTM) and a robust, low-leverage balance sheet (debt-to-equity 0.01; equity ratio 76.73%; ROE 20.10%). Offsetting this, net margin has compressed (14.19% TTM vs. 20.70% prior year) and free cash flow declined (-9.83% TTM), pointing to near-term profitability/cash flow pressure despite modest revenue growth (3.50% TTM).

Income Statement

Corcept Therapeutics shows strong profitability with a high gross profit margin of 98.19% TTM, indicating efficient cost management. However, the net profit margin has decreased to 14.19% TTM from 20.70% in the previous year, reflecting a decline in net income relative to revenue. Revenue growth is modest at 3.50% TTM, suggesting stable but slow expansion. EBIT and EBITDA margins have also decreased, indicating potential challenges in operational efficiency.

Balance Sheet

The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.01 TTM, indicating minimal leverage and financial risk. Return on equity is strong at 20.10% TTM, showcasing effective use of equity to generate profits. The equity ratio of 76.73% TTM highlights a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Operating cash flow remains healthy, but the free cash flow has decreased by 9.83% TTM, suggesting potential cash management issues. The operating cash flow to net income ratio is 0.95 TTM, indicating that cash generation is slightly lagging behind net income. The free cash flow to net income ratio is nearly 1, showing that most of the net income is converted into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	741.17M	675.04M	482.38M	401.86M	365.98M	353.87M
Gross Profit	727.78M	664.16M	475.89M	396.47M	360.70M	348.29M
EBITDA	72.46M	138.29M	108.32M	113.89M	127.95M	130.44M
Net Income	105.19M	139.73M	106.14M	101.42M	112.51M	106.01M
Balance Sheet
Total Assets	823.61M	840.55M	621.52M	583.43M	423.76M	571.73M
Cash, Cash Equivalents and Short-Term Investments	421.68M	383.33M	368.22M	431.67M	223.53M	440.70M
Total Debt	6.36M	6.94M	151.00K	1.14M	526.00K	2.55M
Total Liabilities	191.71M	160.96M	114.81M	81.59M	47.95M	48.39M
Stockholders Equity	631.90M	679.59M	506.70M	501.84M	375.81M	523.34M
Cash Flow
Free Cash Flow	162.57M	195.90M	126.90M	119.91M	167.42M	150.73M
Operating Cash Flow	162.85M	198.07M	127.04M	120.32M	167.89M	151.97M
Investing Cash Flow	17.24M	-177.60M	90.91M	-114.33M	136.13M	-119.26M
Financing Cash Flow	-193.71M	-28.35M	-148.72M	-17.28M	-302.59M	12.21M

Corcept Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 46.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Negative. The current price of 46.22 is above the 20-day moving average (MA) of 41.72, below the 50-day MA of 65.45, and below the 200-day MA of 71.28, indicating a neutral trend. The MACD of -7.14 indicates Negative momentum. The RSI at 43.87 is Neutral, neither overbought nor oversold. The STOCH value of 97.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CORT.

Corcept Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	64 Neutral	$4.80B	52.81	16.47%	―	17.92%	-26.13%
JAZZ	64 Neutral	$10.11B	-27.65	-9.06%	―	4.14%	-179.96%
AXSM	55 Neutral	$9.30B	-40.23	-275.50%	―	65.83%	28.50%
RVMD	55 Neutral	$18.90B	-19.27	-60.76%	―	-100.00%	-44.24%
RYTM	53 Neutral	$6.90B	-34.01	-240.36%	―	54.92%	28.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	50 Neutral	$3.50B	-13.99	-22.60%	―	74.91%	31.54%

Corcept Therapeutics Corporate Events

Corcept Therapeutics Phase 3 ROSELLA Trial Achieves Survival Benefit

On January 22, 2026, Corcept Therapeutics reported that its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its overall survival primary endpoint, with the combination reducing the risk of death by 35% versus nab-paclitaxel alone and extending median overall survival to 16.0 months from 11.9 months, without adding safety burden compared with chemotherapy alone. The trial, which previously met its progression-free survival primary endpoint and enrolled 381 patients across multiple regions, strengthens relacorilant’s clinical profile as an oral, biomarker-agnostic therapy that could reshape the treatment landscape for platinum-resistant ovarian cancer and supports Corcept’s ongoing regulatory reviews in the U.S. and Europe, as well as its broader development strategy for relacorilant and other cortisol modulators in solid tumors and hypercortisolism.

The most recent analyst rating on (CORT) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics Faces FDA Setback for Relacorilant Approval

On December 31, 2025, Corcept Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter for its New Drug Application seeking approval of relacorilant to treat patients with hypertension secondary to hypercortisolism, despite the agency acknowledging that the pivotal GRACE trial met its primary endpoint and that the GRADIENT trial provided confirmatory evidence. The FDA concluded it could not yet make a favorable benefit-risk assessment without additional evidence of effectiveness, a setback that delays U.S. commercialization of relacorilant in hypercortisolism even as the company continues to advance the drug for other indications, including platinum-resistant ovarian cancer, where it has an FDA PDUFA decision date set for July 11, 2026 and a marketing application under review in Europe.

The most recent analyst rating on (CORT) stock is a Hold with a $95.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics Reports Q3 2025 Revenue Growth

On November 4, 2025, Corcept Therapeutics announced its financial results for the third quarter of 2025, reporting a revenue increase to $207.6 million from $182.5 million in the same quarter of 2024. The company has expanded its oncology development programs, including new studies in various cancers, and is approaching significant clinical milestones, such as the New Drug Application for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Despite a decrease in net income compared to the previous year, Corcept is optimistic about meeting the increasing demand for its products and advancing its clinical trials.

The most recent analyst rating on (CORT) stock is a Buy with a $83.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.